Laxmi Dental Q1FY27: consol PAT +24% YoY to ₹10.3 Cr on margin expansion

Laxmi Dental's consolidated Q1FY27 revenue hit a record ₹74.70 Cr, up 13.9% YoY and 1.0% QoQ, while consolidated PAT (including JV share) rose faster at ₹10.32 Cr, up 23.8% YoY and 2.2% QoQ; basic EPS was ₹1.87 versus ₹1.53 a year ago. No exceptional items hit either the current or year-ago quarter. The profit outperformance came from margin expansion: EBITDA-level margin (segment result/revenue) rose to 19.2% from 18.2% YoY, and net margin to 13.4% from 12.4% YoY. The driver was a segment mix shift — Aligners revenue grew 29.1% YoY to ₹24.17 Cr with its segment result up ~187% to ₹6.53 Cr (margin near 27%, roughly doubled from a year ago), while the larger Laboratory business, though still growing revenue 12.8% YoY to ₹50.28 Cr, saw its segment result fall 24.2% YoY to ₹7.70 Cr. Overall margin expansion this quarter therefore masks softness on the lab side. No quarter-specific analyst estimate for Q1FY27 could be located (only a broader FY26 full-year consensus revenue figure near ₹296 Cr exists), so the print cannot be graded against street numbers this quarter. Against management's own May-2026 concall commentary — a past growth benchmark of "16% in a challenging year" and long-term margin targets of EBITDA 18-20%, gross 75-80% and PAT 13-15% with no committed timeline — margins are already tracking within those bands while the 13.9% YoY revenue growth trails the cited 16% reference, a mixed read. Standalone PAT was ₹6.17 Cr against the consolidated ₹10.32 Cr, with subsidiaries and JV shares making up the difference. The same board meeting also noted a Letter of Intent to acquire land at Palghar for ₹6.21 Cr (₹51 Lakh advance paid) toward factory expansion and approved allotment of 59,360 ESOP shares; IPO proceeds utilisation stood at ₹77.97 Cr of the ₹128.17 Cr raised, with ₹50.20 Cr still parked in fixed deposits pending an extension for deployment. Management's press release called this the "highest-ever quarterly" revenue level, attributing performance to broad-based momentum in the Dental Laboratory and Aligner Solutions businesses and flagging profitability improvement "largely on account of a better product mix" — consistent with the segment data showing Aligners driving this quarter's margin gain. Management also cited efforts to strengthen on-ground US leadership.